☰

Marilyn M. Day - Publications

Affiliations: 
2016-2018 National Institutes of Health, Bethesda, MD 
Tree Info Grants Similar researchers PubMed Report error

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Free RB, Cuoco CA, Xie B, Namkung Y, Prabhu VV, Willette BKA, Day MM, Sanchez-Soto M, Lane JR, Laporte SA, Shi L, Allen JE, Sibley DR. Pharmacological characterization of the imipridone anti-cancer drug ONC201 reveals a negative allosteric mechanism of action at the D dopamine receptor. Molecular Pharmacology. PMID 34353882 DOI: 10.1124/molpharm.121.000336  0.663
2020 Prabhu V, Cuoco C, Jung J, Morrow S, Kawakibi AR, Willette B, Day M, Anantharaman L, Charter N, Rucker J, Doranz B, Basken J, Stogniew M, Gilbert M, Free R, et al. DDRE-33. MOLECULAR DIFFERENTIATION OF IMIPRIDONES ONC201 AND ONC206 Neuro-Oncology. 22: ii68-ii68. DOI: 10.1093/neuonc/noaa215.278  0.517
2019 Keck TM, Free RB, Day MM, Brown SL, Maddaluna MS, Fountain G, Cooper C, Fallon B, Holmes M, Stang C, Burkhardt R, Bonifazi A, Ellenberger MP, Newman AH, Sibley DR, et al. Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry. PMID 30883109 DOI: 10.1021/Acs.Jmedchem.9B00231  0.588
2019 Benjamin Free R, Cuoco C, Prabhu V, Willette B, Day M, Anantharaman L, Sulli C, Davidson E, Deacon S, Rucker J, Charter N, Doranz B, Oster W, Stogniew M, Robert Lane J, et al. EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 21: vi89-vi89. DOI: 10.1093/Neuonc/Noz175.365  0.614
2019 Prabhu V, Cuoco C, Jung J, Rahman Kawakibi A, Willette B, Day M, Anantharaman L, Charter N, Rucker J, Doranz B, Oster W, Stogniew M, Gilbert M, Benjamin Free R, Sibley D, et al. DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY Neuro-Oncology. 21: vi67-vi67. DOI: 10.1093/Neuonc/Noz175.271  0.624
2018 Cuoco CA, Free RB, Willette BK, Day MM, Lane JR, Allen JE, Sibley DR. Characterization of the novel anti-cancer therapeutic ONC201 and related analogs as non-competitive antagonists of the D2 dopamine receptor The Faseb Journal. 32. DOI: 10.1096/Fasebj.2018.32.1_Supplement.827.10  0.551
Show low-probability matches.